Journal
JOURNAL OF HYPERTENSION
Volume 39, Issue 8, Pages 1717-1724Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/HJH.0000000000002866
Keywords
angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; COVID-19 incidence
Categories
Funding
- National Natural Science Foundation of China (NSFC) [71972164, 72042018]
- Health and Medical Research Fund of the Food and Health Bureau of Hong Kong [16171991]
- Innovation and Technology Fund of Innovation and Technology Commission of Hong Kong [MHP/081/19]
- National Key Research and Development Program of China, Ministry of Science and Technology of China [2019YFE0198600]
- Collaborative Research Fund (CRF) of Research Grants Council of Hong Kong [C7154-20G]
Ask authors/readers for more resources
The study found a significant relationship between ACEI/ARB use and COVID-19 positivity and severe disease after adjusting for significant confounders. There were no significant differences in COVID-19 positivity or disease severity between ACEI and ARB use.
Background: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be associated with higher susceptibility of COVID-19 infection and adverse outcomes. We compared ACEI/ARB use and COVID-19 positivity in a case-control design, and severity in COVID-19 positive patients. Methods: Consecutive patients who attended Hong Kong's public hospitals or outpatient clinics between 1 January and 28 July 2020 for COVID-19 real time-PCR (RT-PCR) tests were included. Baseline demographics, past comorbidities, laboratory tests and use of different medications were compared between COVID-19 positive and negative patients. Severe endpoints for COVID-19 positive patients were 28-day mortality, need for intensive care admission or intubation. Results: This study included 213 788 patients (COVID-19 positive: n = 2774 patients; negative: n = 211 014). In total, 162 COVID-19 positive patients (5.83%) met the severity outcome. The use of ACEI/ARB was significantly higher amongst cases than controls (n = 156/2774, 5.62 vs. n = 6708/211014, 3.17%; P < 0.0001). Significant univariate predictors of COVID-19 positivity and severe COVID-19 disease were older age, higher Charlson score, comorbidities, use of ACEI/ARB, antidiabetic, lipid-lowering, anticoagulant and antiplatelet drugs and laboratory tests (odds ratio >1, P < 0.05). The relationship between the use of ACEI/ARB and COVID-19 positivity or severe disease remained significant after multivariable adjustment. No significant differences in COVID-19 positivity or disease severity between ACEI and ARB use were observed (P > 0.05). Conclusion: There was a significant relationship between ACEI/ARB use and COVID-19 positivity and severe disease after adjusting for significant confounders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available